Form 4: Catalyst Pharmaceuticals Executive Sells Shares on Open Market

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold shares on the open market for personal reasons.

Summary

• Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, executed transactions involving the company's stock.
• On March 5, 2025, Ingenito exercised options to purchase 44,904 shares at $2.24 per share and sold the same amount on the open market at a weighted average price of $22.09.
• Following these transactions on March 5, Ingenito directly owns 68,873 shares of common stock and 970,378 options.
• On March 6, 2025, Ingenito exercised options to purchase 180,096 shares at $2.24 per share and sold the same amount on the open market at a weighted average price of $21.67.
• Following these transactions on March 6, Ingenito directly owns 68,873 shares of common stock and 790,282 options.
• The sales were conducted for personal reasons and not due to any disagreement with the company.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider transactions. The sentiment is neutral as it simply reports facts without expressing any positive or negative outlook.

Management Comments

• Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Industry Context

Executive stock sales are a common occurrence, and investors often monitor these transactions for insights into management's perspective on the company's future prospects. However, in this case, the executive stated the sales were for personal reasons.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, but the executive stated the sales were for personal reasons.

Key Dates